{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-049529","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2024-04-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.726061+00:00","generated_at":"2026-06-03T16:15:07.286755+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"NRx Pharmaceuticals prices $2.0M public offering of common stock at $3.30 per share","bullets":["Underwritten public offering of 607,000 shares at $3.30/share; gross proceeds ~$2.0M before expenses.","Underwriters granted 45-day option for up to 91,050 additional shares at same price to cover over-allotments.","Company will issue to representative EF Hutton a warrant to purchase up to 30,350 shares (5% of shares sold) at $3.63/share.","Net proceeds to be used for working capital, general corporate purposes, and potential repayment of Streeterville Capital note.","Offering closed on April 19, 2024; shares sold under existing effective shelf registration statement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-049529","json":"https://secwatch.observer/filing/0001104659-24-049529.json","markdown":"https://secwatch.observer/filing/0001104659-24-049529.md","text":"https://secwatch.observer/filing/0001104659-24-049529.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000110465924049529/0001104659-24-049529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000110465924049529/tm2412274d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T16:15:07.286755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5e2dc65f0ffa45a4ae1ce867ee595fb1caf8b3e9","claim":"NRX Pharmaceuticals, Inc. entered into Underwriting Agreement with EF Hutton LLC valued at approximately $2.0 million (effective 2024-04-18).","evidence_excerpt":"On April 18, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with EF Hutton LLC (the “ Representative ”), as the representative of the several underwriters named therein (the “ Underwriters ”), relating to an underwritten public offering (the “ Offering ”) of 607,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (“ Common Stock ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000110465924049529/0001104659-24-049529-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"EF Hutton LLC"},{"label":"Value","value":"approximately $2.0 million"},{"label":"Effective","value":"2024-04-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}